ACVR2B 10mg/vial 1 Vial by Bio-Peptide

Usage

1. Confirm research purpose: ACE-031 is an experimental ACVR2B decoy receptor protein; confirm your protocol falls within applicable research regulations before proceeding.
2. Prepare the reconstitution environment: Work on a clean, alcohol-swabbed surface; gather bacteriostatic water, a 29–31 gauge insulin syringe, and the ACE-031 vial.
3. Reconstitute the lyophilised powder: Inject 1–2 mL of bacteriostatic water slowly along the inner vial wall; swirl gently for 30–60 seconds until fully dissolved — never vortex or shake.
4. Calculate your dose volume: Divide the total reconstituted volume by 10 mg to determine concentration per mL; draw the target dose volume into an insulin syringe.
5. Administer subcutaneously: Pinch abdominal skin, insert the needle at 45°, and inject slowly; rotate sites with each subsequent dose to limit tissue stress.
6. Store and log: Refrigerate the reconstituted vial at 2–8 °C immediately after use; record dose, date, and any observed responses in a research log; discard after 28 days.

Warnings

Frequently asked questions

What does follistatin block in the body compared to ACE-031?

Follistatin-344 binds and neutralises myostatin protein directly in extracellular space, preventing it from reaching any receptor. ACE-031 acts as a decoy receptor, intercepting myostatin, activin A, and GDF-11 before they bind membrane ACVR2B. The key difference is breadth: ACE-031 captures a wider set of TGF-β superfamily ligands, whereas follistatin-344 is more selective for myostatin and related proteins.

How significant is the muscle-growth effect of myostatin inhibition with ACVR2B?

Preclinical rodent studies using ACVR2B neutralisation documented lean mass gains of 20–30 % within several weeks (Lee & McPherron, 2001, PNAS) — among the largest pharmacologically induced increases recorded in muscle biology research. In human Duchenne Muscular Dystrophy trials (Acceleron Pharma, Phase 2), lean mass increases were observed but the trial was discontinued before efficacy endpoints were fully evaluated in healthy subjects.

Why are myostatin-blocking peptides like ACE-031 still considered experimental?

ACE-031's Phase 2 clinical trial was halted after participants reported bleeding-related adverse events — nosebleeds, gum bleeding, and telangiectasias — linked to off-target suppression of activin and GDF signalling in vascular tissue. Because ACVR2B is expressed beyond skeletal muscle, broad ligand capture by ACE-031 affects vascular homeostasis. This off-target profile means no approved human therapeutic application currently exists, and the compound remains a research-only agent.

How is ACE-031 10mg vial reconstituted and stored after opening?

Reconstitute the lyophilised powder by injecting 1–2 mL of bacteriostatic water slowly along the vial wall — do not shake; swirl gently. Once reconstituted, store the vial at 2–8 °C (standard refrigerator) and use within 28 days. Draw doses using an insulin syringe to achieve precise micro-volume accuracy. Never freeze a reconstituted vial; freeze only the dry, unreconstituted powder if long-term storage is required.

What injection technique is recommended for insulin-syringe dosing of ACE-031?

A 29–31 gauge insulin syringe is standard for ACE-031 research protocols, enabling sub-milligram dose accuracy. Subcutaneous administration into the abdominal pinch is the most commonly documented route in peptide research contexts. Rotate injection sites with each dose to minimise localised irritation. Wipe the vial septum with an alcohol swab before each draw, and allow refrigerated solution to approach room temperature before injection to reduce discomfort. (2) angle_used

Manufacturer

When Bio-Peptide's founders structured the company's release criteria, they made a decision that distinguished their operational model from the majority of European research-peptide producers: every batch — regardless of compound complexity — would clear two externally commissioned laboratory analyses before a single vial could be labelled or distributed. That requirement was written into the workflow as a precondition, not a post-market option. For ACE-031, a recombinant fusion protein with a more complex molecular architecture than most single-chain peptides, that two-checkpoint framework carries particular weight. The first checkpoint is HPLC (High-Performance Liquid Chromatography) analysis, commissioned from an independent laboratory and tasked with confirming the fusion protein's molecular sequence fidelity alongside an acceptable purity percentage for the specific batch. The second is a LAL (Limulus Amebocyte Lysate) endotoxin assay, certifying that bacterial endotoxin levels fall within injection-grade safety thresholds — a standard that matters acutely for a compound intended for parenteral research use. Both analyses generate batch-specific documentation that travels with the product. This structure reflects the founding philosophy Bio-Peptide applied from the outset: that the credibility of a research supplier rests not on catalogue breadth, but on the verifiability of what is inside each vial.